Joinn Laboratories (China) Co (SHSE:603127) Moat Score: 0/10 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603127 Joinn Laboratories (China) Co Ltd SHSE:603127
78 GF Score
Price ¥41.54
GF Value ¥17.43
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Joinn Laboratories (China) Co Moat Score?

Joinn Laboratories (China) Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Joinn Laboratories (China) Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Joinn Laboratories (China) Co might have No Moat - No discernible moat.

Joinn Laboratories (China) Co  (SHSE:603127) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Joinn Laboratories (China) Co Moat Score Related Terms

SHSE:603127
78GF Score
Joinn Laboratories (China) Co Ltd SHSE:603127
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?

Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued. The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43. GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.

Key valuation signals for SHSE:603127:

  • Moat Score: 0
  • GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Joinn Laboratories (China) Co Business Description

Other Exchanges 06127:Hong Kong
Address A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score

Get the complete analysis for SHSE:603127

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥41.54
Price
¥17.43
GF Value